Phase-Transition Timing: Find Biotechs Before They Buy

How CRO, CDMO and eClinical sellers find biotechs 6 to 24 months before a phase transition: windows by service, public signals and a list-building routine.

Semir Jahic··13 min read

To find biotechs before they buy, work backwards from the next phase transition. A biotech hires its vendors for a new phase months before the first patient is dosed, so the useful list is companies whose current trial completes, or whose next trial starts, 6 to 24 months from today. Which end of that range you need depends on what you sell: eClinical and central-lab vendors work the short end, CDMOs, biometrics teams and GxP IT vendors the long end. The dates are public. ClinicalTrials.gov publishes estimated start and primary completion dates for registered trials, the EU runs its own public trial search for Europe, and financing rounds, readouts and hiring tell you whether the next phase is funded and staffed.

TL;DR: Pick the window for your service from the table below. Pull industry-sponsored trials whose primary completion (for the next-phase decision) or start date (for the study build) falls in that window. Keep phase and date on the same trial. Roll trials up to sponsors, check money and hiring, and refresh monthly, because registry dates move. You can do all of it by hand on ClinicalTrials.gov. Salesmotion for Life Sciences runs the same search in Discover with same-trial filters and preset windows up to the next 24 months.

This is the most frequent life-sciences question we hear. Between 21 October and 18 November 2026, 5 of the 8 life-sciences organisations we spoke with asked some version of it: when does a sponsor reach its next phase, so we can talk to them before a vendor is chosen? A business development rep at a CRO put the cost of getting it wrong plainly: "if we reach out too late, I don't care how well my messages ... If they've already signed for like their phase two study, they're just not going to be interested."

Why Do Biotechs Buy Around Phase Transitions?

A phase transition is the moment a programme's needs change all at once: a larger study, new countries, more sites, new manufacturing scale, new data and quality systems. Most of those services are bought before the new phase starts, and many are bought only once per programme.

The money arrives in the same pattern. A clean Phase 2 readout is usually followed by a financing or a partnership that pays for Phase 3, and the vendor shortlist is drawn up while that money is being raised.

The phase lengths also tell you how much time you have. The BIO, Informa Pharma Intelligence and QLS Advisors report on clinical development success rates 2011 to 2020 (February 2021, 12,728 phase transitions from 9,704 programmes) found:

PhaseAverage time in phaseShare that advanced to the next phase
Phase 12.3 years52.0%
Phase 23.6 years28.9%
Phase 33.3 years57.8%
NDA or BLA (regulatory review)1.3 years90.6%

Two points follow. A Phase 2 programme runs for years, so a 6 to 24 month window catches each sponsor at a known point in a long arc. And fewer than one in three Phase 2 candidates advanced in that data, so a Phase 2 completion date tells you when the decision comes, not which way it goes. Confirm the outcome before you pitch Phase 3 services.

Which Window Fits Which Service?

Each service has its own window, set by how long the sponsor needs to choose and onboard a vendor before the work starts. The table below gives working rules of thumb, built from the phase lengths above. Treat them as starting points and tighten them with your own won-deal history.

What you sellEvent to time againstWhen to be in the conversation
Full-service CROAward for the next trialFrom the previous phase's readout onward, often 6 to 12 months before first patient in
Biometrics, biostatistics, adaptive designProtocol and statistical analysis plan for the next phase9 to 18 months before the next trial starts, often before the current readout
CDMO and clinical supplyScale-up for a larger trial, then commercial manufacturing12 to 24 months ahead: drug substance and drug product lead times are long
Specialty CROs, bioanalytical and central labsStudy startThe months and weeks before first patient in, when these scopes are often decided
eClinical (EDC, RTSM, eCOA)Study build3 to 6 months before first patient in, often alongside or after CRO selection
Publications and medical communicationsReadouts, congress abstracts, filing6 to 18 months before topline data and through the regulatory filing
GxP IT, quality systems, validationLate Phase 3 and the build-up to a commercial company12 to 24 months before the expected filing
Pharmacovigilance and post-marketingFiling and approval6 to 18 months before the expected approval

For the launch side, our guide to PDUFA, NDA and BLA sales triggers maps the regulatory clock month by month. For the CRO case, how to find sponsors before they pick a CRO covers the events between readout and RFP.

Which Public Signals Mark a Coming Phase Transition?

Six public signals do most of the work. The first three come from trial registries and tell you when. The last three tell you whether the next phase is real: funded, announced and staffed.

  1. Primary completion date. The estimated date the last participant is examined for the primary outcome. It sets the readout window, and the readout sets the next-phase decision. Sponsors of covered trials must update the primary completion date within 30 calendar days of reaching it, so the estimate becomes actual soon after the event.
  2. Start date and "not yet recruiting" status. A registered trial that has not started yet is the clearest sign of a study being built right now. For the main CRO award it may already be late. For eClinical, labs, specialty CROs and site networks it is often right on time.
  3. A phase transition in the registry. A sponsor that ran a Phase 2 and now registers a Phase 3 in the same indication has made the decision you were waiting for. The registration also shows countries and site regions, which tells you whether your geography is in scope.
  4. Readouts. Topline results arrive by press release, at congresses and, for public companies, in SEC filings. A positive readout moves the next-phase work from "maybe" to "planning"; a negative one ends it.
  5. Financing rounds. A Series B or C, an IPO, a follow-on offering or a partnership with milestone payments pays for the next phase. The size of the round tells you how far it reaches. Our biotech funding tracker lists recent rounds with the source for each, and funding rounds as a sales trigger explains how to read them.
  6. Hiring. Job posts show which function is being built: clinical operations and trial managers before a new study, biostatistics before a protocol, CMC and supply chain before scale-up, quality and regulatory before a filing, medical affairs before launch.

Two cautions apply to registry data. Estimated dates slip, often by months, so a date is a forecast and needs a monthly re-check. And many trials are run by academic centres with their own procurement, so filter to industry sponsors first; industry vs academic sponsors explains why that matters for a CRO pipeline.

How Do You Build the List Step by Step?

You can build a phase-transition list by hand in an afternoon. The steps below use only free public registries. The work that takes time is the refresh, not the first pull.

1. Fix your service and window. Pick one row from the table above. Example: a biometrics CRO that wants Phase 2 sponsors whose trial completes in the next 12 months, because their Phase 3 protocol will be written around the readout.

2. Search ClinicalTrials.gov. Use the search filters to set the condition or therapeutic area, the phase (Phase 2), the study status (recruiting, or active and not recruiting), and limit results to industry sponsors. Then set a date range on primary completion for a readout window, or on study start for a study-build window. Download the results as a spreadsheet.

3. Or use the free API for an exact, repeatable query. ClinicalTrials.gov publishes a public data API. This query returns industry-led Phase 2 trials that are recruiting or active, with a primary completion date in the first half of 2027:

https://clinicaltrials.gov/api/v2/studies
  ?filter.advanced=AREA[Phase]PHASE2 AND AREA[LeadSponsorClass]INDUSTRY
     AND AREA[PrimaryCompletionDate]RANGE[2027-01-01,2027-06-30]
  &filter.overallStatus=RECRUITING,ACTIVE_NOT_RECRUITING
  &fields=NCTId,LeadSponsorName,Phase,PrimaryCompletionDate,Condition

Remove the line breaks and URL-encode the spaces before you run it. Save the query, because next month you will run it again.

4. Repeat for Europe. Trials run in the EU are published in the EU clinical trials search, run by the European Medicines Agency. Check it for sponsors in your therapeutic area that do not appear on ClinicalTrials.gov, and add them to the same sheet.

5. Keep phase and date on the same trial. This is the step most homemade lists get wrong. A sponsor with a Phase 1 trial completing next month and a Phase 2 trial completing in 2029 is not a "Phase 2 completing soon" account. Filter trial by trial first, and only then roll up to the company.

6. Roll trials up to sponsors. Group by lead sponsor and keep one row per company, with the trial that qualified it, its NCT or EU trial number, the date and the indication. Clean up sponsor names: the same company often appears under two or three spellings.

7. Check the money and the people. For each sponsor, add the last financing round and its date, and whether the company is hiring in the function you serve. A sponsor with a readout in 9 months, a fresh Series B and three open clinical operations roles goes to the top. A sponsor with a readout and no cash runway goes to "watch".

8. Tier and assign. Tier 1: inside your window, funded, hiring. Tier 2: inside the window, one of the two missing. Tier 3: enters the window within two quarters. Give each Tier 1 account an owner.

9. Refresh monthly. Re-run the saved query, compare dates with last month and move accounts between tiers. A slipped completion date can push a sponsor out of your window; a newly registered Phase 3 can pull one in. For a quarterly view of the whole market by indication and phase, see clinical pipeline analysis by indication and phase.

Where Does Salesmotion Help?

Salesmotion for Life Sciences runs the search in steps 2 to 6 for you and keeps watching the accounts you choose. It does two jobs: Discover finds sponsors by trial timing, and trial signals tell you when a tracked sponsor moves.

Discover's trial filters. Discover finds sponsors from the trials they lead, using trial data from ClinicalTrials.gov and the EU Clinical Trials Register. A search can hold up to five trial filters. Each filter describes one trial the company leads as lead sponsor, so phase and timing always match on the same trial (step 5 above, done for you). A trial filter can combine:

  • phase and status
  • a start window and a completion window
  • indication and therapeutic area
  • site region and country

The windows are presets that run from today: the past 90 days, 6 months or 12 months, and the next 90 days, 6 months, 12 months or 24 months. To work a service window from the table, choose the preset that covers it, then tier the results by how close each trial's date is. For example, a biometrics CRO can search for Phase 2 trials completing in the next 12 months; a CDMO can search for Phase 3 trials starting in the next 24 months; an eClinical vendor can search for trials starting in the next 6 months in the countries it supports.

Trial signals on tracked accounts. Once a sponsor is on your account list, the Signal Agent flags four trial events, each with the registry record as its source:

SignalWhat it meansWho it matters to
Trial StartedThe account registered or started a new clinical trialCentral and bioanalytical labs, eClinical, specialty CROs
Phase TransitionThe account advanced a programme to a later clinical phaseEvery row of the service table, especially CROs and CDMOs
Trial ReadoutThe account completed a trial, suggesting a readout momentBiometrics, medical communications, regulatory
Site ActivationA recruiting trial has an unusually broad active site footprintMonitoring, recruitment and site services

The same account brief also carries the money and hiring checks from step 7, plus readout news: funding rounds, news and press releases, SEC filings and job posts, so the "is it funded and staffed?" check sits next to the trial date. The Outreach Agent then drafts a first message that names the event, for a rep to review and send.

The CRO page shows how clinical research teams run this as a weekly routine, and the CDMO and analytical page covers manufacturing and lab services.

What Mistakes Make a Timing List Useless?

Four mistakes account for most lists that look right and do not produce meetings.

  • Matching phase and date on different trials. The list fills with companies that have "a Phase 2" and "a trial completing soon", but not a Phase 2 completing soon. Always filter trial by trial.
  • Treating estimated dates as fixed. Registry dates are estimates until the event happens. Re-check monthly and expect slips.
  • Ignoring trials with no phase. Many registry records list no phase, for example device and observational studies. Decide whether they belong in your market and handle them as a separate list instead of letting them drop out silently.
  • Calling every account in the window with the same message. A sponsor 18 months from a Phase 3 start needs a conversation about protocol design or supply strategy. A sponsor 4 months away needs proof you can start on time. Match the message to where they are.

Frequently Asked Questions

How far ahead of a phase transition should a CRO contact a biotech?

As a working rule, from the current trial's readout onward, often 6 to 12 months before the next trial's first patient in. Biometrics CROs that help design the protocol should start earlier, 9 to 18 months ahead. Specialty and lab scopes are often decided in the weeks around first patient in, by which time the main CRO is usually chosen.

Where can I find biotechs entering Phase 3?

Look for industry-sponsored Phase 2 trials with a primary completion date in the next 6 to 12 months, and for newly registered Phase 3 trials that are not yet recruiting. ClinicalTrials.gov filters by phase, status, sponsor type and date, and the EU clinical trials search covers trials run in Europe. Confirm each readout and the financing behind the next phase before you pitch Phase 3 services.

How long does each clinical trial phase take?

Across 2011 to 2020, the BIO, Informa and QLS Advisors report measured an average of 2.3 years in Phase 1, 3.6 years in Phase 2, 3.3 years in Phase 3 and 1.3 years in regulatory review: 10.5 years from Phase 1 to approval. Timelines vary widely by disease area.

Are ClinicalTrials.gov dates reliable enough for sales planning?

They are reliable enough to set a window, not to set a date. Future start and completion dates are sponsor estimates and often slip. Sponsors of covered trials must update the primary completion date within 30 days of reaching it, so actual dates appear soon after the event. Re-run your search every month.

What signals besides trial dates show a biotech is about to buy?

Financing rounds, readouts and hiring. A recent raise shows the next phase is paid for, a positive readout shows the decision has been made, and job posts in clinical operations, biostatistics, CMC or quality show which function is building. A sponsor with all three inside your window is your best account this quarter.

Can Salesmotion filter for Phase 2 trials completing in the next 12 months?

Yes. Discover's trial filters match phase, status and completion window on the same lead-sponsored trial, with preset windows of the next 90 days, 6 months, 12 months or 24 months. You can also filter by indication, therapeutic area, site region and country, and combine up to five trial filters in one search.

About the Author

Semir Jahic
Semir Jahic

CEO & Co-Founder at Salesmotion

Semir is the CEO and Co-Founder of Salesmotion, a B2B account intelligence platform that helps sales teams research accounts in minutes instead of hours. With deep experience in enterprise sales and revenue operations, he writes about sales intelligence, account-based selling, and the future of B2B go-to-market.

Follow on LinkedIn

Related articles

Ready to transform your account research?

See how Salesmotion helps sales teams save hours on every account.

Book a demo